Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases (sbrtlungfff)
Risk Adapted Free Flattering Filter Based Stereotactic Ablative Radiotherapy (Sabr) in Stage i Nsclc and Lung Metastases
Sponsor: Institut Català d'Oncologia
Listed as NCT01823003, this PHASE2 trial focuses on Carcinoma, Non-Small-Cell Lung and Neoplasm Metastasis and remains ongoing. Sponsored by Institut Català d'Oncologia, it has been updated 9 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Unknown Status → Active Not Recruiting
-
Jan 2019 — Sep 2019 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut Català d'Oncologia
For direct contact, visit the study record on ClinicalTrials.gov .